Anaptys Reports Q2 2026 Results, Provides Update on Litigation and Separation

What happened

AnaptysBio announced second quarter and transitional fiscal year 2026 financial results and provided a business update, as is typical for the company's quarterly disclosures. The announcement follows the company's prior disclosure of a July 2026 trial date in the GSK/Tesaro royalty dispute and an anticipated $75 million Jemperli sales milestone accrual in Q4 2025, but the press release does not disclose specific financial figures or substantive updates on these catalysts. The company continues to grapple with the fact that most reported Jemperli royalty and milestone revenue is non-cash under the royalty monetization agreement, carried as a nonrecourse liability with an estimated 30.5% effective rate as of September 30, 2025. Management's comments likely reiterate the planned separation into two public entities by year-end 2026, but without SEC registration filing specifics the plan remains conditional and reversible, a key risk flagged in the master report. The market's focus remains on whether the company confirms the $75M milestone accrual, provides litigation updates, and demonstrates progress on separation execution, because those factors drive the stock's risk-adjusted value.

Implication

The press release provides little new information beyond the fact that results were reported, so the thesis remains WAIT with the same key catalysts unresolved. Confirmation of the $75M Jemperli milestone accrual in the financial statements would improve cash optionality, but the expected $50M milestone payable to Sagard partially offsets that benefit. The litigation trial in July 2026 remains a binary risk to royalty economics, and the company has not yet disclosed whether the motion to dismiss was granted or denied. The separation plan is still conditional on SEC registration effectiveness, and without a filing, the value-unlock path is not yet de-risked. Until these uncertainties are resolved, the stock's fair value remains around $56 per the base case, with an attractive entry below $48 and trim above $65.

Thesis delta

The thesis remains largely unchanged, as the press release does not provide specific financial or strategic updates that would alter the WAIT rating. The core concerns around monetization accounting, litigation risk, and separation execution persist, and the market still requires confirmation of the $75M milestone and legal clarity before a re-rating is justified. However, the mere passage of time shortens the window to key catalysts, and investors should monitor subsequent filings for the detailed disclosures that will determine whether the bull or bear case prevails.